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Abstract
Context: The risk of laboratory cross-contamination may limit the availability of assisted conception for couples infected 
with chronic viruses. However, assisted conception is the standard of care for people living with human immunodeficiency 
virus (HIV) to minimize risk of transmission or reinfection.
Aims: To assess the burden of viral infection among couples that present for assisted reproductive technology (ART) 
with a view to evaluating implications for their care.
Settings and Design: A cross-sectional descriptive study carried out among 138 couples at a private fertility clinic in 
Nigeria.
Materials and Methods: Screening for HIV, hepatitis B virus (HBV) and hepatitis C virus were carried out among 
these clients. The males’ seminal parameters were analyzed according to World Health Organization (WHO) criteria.
Statistical analysis Used: Statistical Package for Social Sciences was employed. Analysis was by Chi-square test; 
statistical significance was set at 0.05.
Results: Viral infections were found in 10/138 women (7.2%) and 15/138 (10.9%) men. The most prevalent infection 
was HBV. Twenty-one couples were sero-discordant. Two couples had concordant HIV and HBV infections, respectively. 
There was no significant association between sperm quality and chronic hepatitis infection.
Conclusion: Nearly a fifth of the couples had at least one partner infected with a chronic virus – a proportion significant 
enough to demand attention. Apart from separate laboratory and storage facilities, basic principles to minimize 
transmission are recommended: HBV vaccination in sero-discordant partners of HBV carriers (and immunoprophylaxis 
for the baby) and antiretroviral therapy for HIV-positive partners to reduce the viral load before fertility treatment is 
commenced.
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Introduction
Assisted reproductive technology (ART) has been available 
in Nigeria for the past couple of decades. For those whom 
it is affordable for, it has done much to assuage the scourge 
of infertility in the study area. The absence of a local 
regulatory agency or a national protocol leaves most 
practitioners having to borrow protocols and practices from 
other countries who have established guidelines. One of the 
thorny issues is the management of patients that have viral 
infections, especially human immunodeficiency virus (HIV), 
Hepatitis B virus (HBV), and Hepatitis C virus (HCV). 
The misgivings are those of cross‑contamination in the 
laboratory, vertical transmission to the resultant offspring 
and possible deleterious effect of pregnancy on the progress 
of the disease (which may lead to the offspring being 
orphaned early in life). HIV,[1] HBV,[2] and potentially, 
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HCV[3] infection have been described to have occurred 
during donor insemination. Laboratory cross‑contamination 
of HCV between in vitro fertilization (IVF) patients has also 
been demonstrated.[4] Some workers also demonstrated 
a decreased ovarian response during IVF/intracytoplasmic 
sperm injection (ICSI) cycles of HCV‑seropositive 
patient.[5] Carriers of chronic viral infections have therefore 
been viewed as a risk, which for many years has led to 
screening for these viruses and selection of candidates 
for gamete donation. However, with improved level of 
care through availability of highly active antiretroviral 
therapy (HAART), those infected with HIV are now able to 
seek procreation. Many countries’ guidelines have evolved 
over the past decade and now it is generally recommended 
that samples from viral carriers be processed in a separate 
laboratory or designated space within the main laboratory, 
utilizing dedicated equipment, to minimize the risk of cross 
contamination, and that there are separate storage facilities, 
a different one for each infection.[6,7] The Ethics Committee 
of the American Society for Reproductive Medicine[8] has 
stated that fertility services cannot be withheld ethically 
from individuals with chronic viral infections, including 
HIV, if a center has the resources to provide care. Those 
centers that do not have the resources or facilities to provide 
care should facilitate referral to a center with protocols in 
place to manage such patients.[5]
Assisted reproduction in Nigeria has largely been limited 
to relatively small, private, nonacademic centers. The 
practice had mostly been to desist from offering care to 
patients infected with these chronic viruses, because 
of the fear of cross‑contamination, as separate storage 
facilities are not available. The magnitude of the problem 
has grown, however, as people living with HIV in Nigeria 
have begun to benefit from antiretroviral therapy, and are 
now able to pursue their desire for procreation. Standard 
of care for these individuals involve assisted reproductive 
techniques, to minimize risk of transmission or reinfection 
within the couple. This study aims to assess the burden of 
viral infections among couples that present for ART with 
a view to evaluating implications for their care.
Materials and Methods
This was a cross‑sectional, descriptive study of 138 consenting 
couples who presented consecutively to a private fertility 
clinic in Nigeria for infertility evaluation and treatment 
over a 5‑month period. They were all apparently healthy 
patients; none of them were on chronic medication. They 
were counseled and their consent was taken for investigations 
and management and for the use of their data for clinical audit 
and evaluation. Patients at this facility are informed that there 
will be no withdrawal of services or loss of benefits to them 
if they decline to have their data used for research purposes. 
Opt‑out method of HIV screening was used.
As part of their routine evaluation, rapid screening for HIV 
was done in parallel with SD Bioline HIV 1/2 3.0 (Standard 
Diagnostics Inc., Kyonggi‑do, Korea) and Determine 
HIV‑1/2TM (Abbott Diagnostics, North Chicago, IL, USA). 
Hepatitis B surface antigen (HBsAg) and Hepatitis C virus 
antigen were screened for with Diaspot DS‑HB301 and 
DS‑HC302 strips (Sam‑Tech Diagnostics, Nairobi, Kenya), 
respectively. Samples with reactive results were sent out for 
confirmation with western blot for HIV and polymerase 
chain reaction for HCV, respectively. Samples that were 
positive for HBsAg were tested for Hepatitis B envelope 
antigen (HBeAg) and antibody (anti‑HBe).
The results for the men were compared with their seminal 
fluid analyses; which were performed according to standard 
World Health Organization (WHO) criteria.[9]
Results
A total of 276 individuals (i.e., 138 men and women, 
respectively) were recruited into the study. Two women (1.4%) 
tested positive for HIV, and one (0.7%) for HCV [Table 1]. The 
most prevalent viral infection was HBV; with 11 men (8%) 
and 7 women (5.1%) testing positive. In all, 10 women (7.2%) 
and 15 (10.9%) men had a chronic viral infection. Infection 
with either HBV or HCV was reported as chronic hepatitis. 
Sero‑discordance between the couples is also shown. One 
couple was sero‑discordant for two infections; the husband 
tested positive for HBV infection, while the wife tested positive 
for HIV. Both partners of another couple tested positive for 
HIV (this male partner was the only male among the study 
subjects that was infected with HIV), while another couple 
had HBV infection. Table 2 shows the association between 
chronic hepatitis infection and sperm quality. Fourteen men 
had chronic hepatitis. There were no significant associations 









no of couples (%)
HIV
Positive 1 (0.7) 2 (1.4) 1 (0.7)
Negative 137 (99.3) 136 (98.6)
HBV
Positive 11 (8.0) 7 (5.1) 16 (11.6)
Negative 127 (92.0) 131 (94.9)
HCV
Positive 3 (2.2) 1 (0.7) 4 (2.9)
Negative 135 (17.8) 137 (99.3)
Chronic hepatitis
Positive 14 (10.1) 8 (5.8)
Negative 124 (89.1) 130 (94.2)
HIV=Human immunodeficiency virus, HBV=Hepatitis B virus, 
HCV=Hepatitis C virus
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with sperm count or motility or the presence of white blood 
cells in semen with chronic hepatitis.
Discussion
Nearly a fifth of the couples presenting to this clinic had 
at least one partner infected with a virus. This proportion 
is significant enough to demand attention. Hepatitis 
B was the most prevalent of the viral infections that 
were detected; this is what usually exists in the general 
population.[10]
In this study, sperm parameters were not influenced by chronic 
viral infection, similar to findings by Garrido et al.[11] One 
must keep in mind, however, that these subjects presented 
on account of infertility, and were being compared with 
other infertile couples. Other authors have assessed sperm 
parameters in voluntarily infertile couples (i.e., those 
consistently using barrier contraception to limit the risk 
of transmission of the virus), who now present for assisted 
reproduction as a safe option for procreation. Significantly 
higher rates of abnormal seminal parameters were found in 
these studies, when they were compared with fertile men 
who do not have these viral infections.[12,13] This emphasizes 
further, the need for assisted reproduction in these couples 
and why they should not be denied care.
Apart from separate laboratory and storage facilities, 
basic principles in minimizing horizontal and vertical 
transmission would need to be followed: Antiretroviral 
therapy for HIV‑positive partners to reduce the viral load 
to an almost undetectable level at which transmission is 
less likely; HBV vaccination in sero‑discordant partners of 
HBV carriers (and immunoprophylaxis for the baby); and 
use of peginterferon‑alpha and ribavirin in chronic HCV 
carriers to reduce the viral load before fertility treatment 
is commenced.[6] Patients with HBV and HCV require 
a referral to a hepatologist for treatment and follow‑up in 
view of the long‑term risk of cirrhosis and liver failure. The 
cost of all this medication in the study environment is often 
prohibitive; but it is hoped that patients who can afford 
privately funded assisted conception may be able to afford 
the treatment for these viral infections. The most feasible 
therapy that could be ensured would be for HIV, as there 
are many dedicated governmental and nongovernmental 
facilities that provide HIV care, including HAART, at little 
or no cost to people living with HIV/AIDS. Clients attending 
the PEPFAR (the US President’s Emergency Plan for AIDS 
Relief) clinic at our tertiary hospital, who desire to procreate, 
are optimized with administration of HAART (if eligible) 
and management of opportunistic infections, while their 
viral load is monitored. Artificial insemination is offered to 
sero‑discordant couples with HIV‑positive female partners. 
However, the management of concordant couples or 
discordant ones with an infected male is more challenging, 
as referral for further assisted reproduction is limited by 
lack of centers with facilities for managing clients with viral 
infections. Most patients end up having unprotected timed 
intercourse, which expectedly has its risks.[14]
Consecutive recruitment, as was done, limits the study as it 
may be biased. Moreover, this was a cross‑sectional study, 
and is therefore limited in being able to evaluate whether 
there were any differences in the fertility treatment outcome 
between couples infected with chronic viruses and those 
who were not infected. This may have further implications 
for management.
However, the findings do suggest that apparently healthy 
individuals may have medical disorders that may predispose 
them to serious health consequences in the future. One may 
conclude that providers of assisted conception would need 
to counsel and refer patients in whom routine screening 
reveals chronic illnesses and viral infections. Further 
research may be useful to identify the implications of these 
infections on infertility and its management.
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Azoospermia 2 (14.3) 10 (8.1) 0.743 0.863
Severe 
oligozoospermia
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